Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Zambetti

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
American Journal of Clinical Oncology|June 1, 1990
Cisplatin and cyclophosphamide in advanced ovarian carcinoma: activity and toxicity of an ambulatory regimenM Zambetti, L Gianni, F Di Re, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1986
Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancerG Bonadonna, P Valagussa, G Tancini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2005
Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic processR Demicheli, R Miceli, A Moliterni, et al.
The International Journal of Biological Markers|October 1, 1989
Detection of Lewis(a) antigen in sera of ovarian carcinoma patients by MOv2-MOv8 double-determinant radioimmunoassayL Mantovani, V Azzini, S Canevari, et al.
Gynecologic Oncology|November 1, 1992
Nondysgerminomatous tumors of the ovary treated with cisplatin, vinblastine, and bleomycin: long-term resultsG De Palo, M Zambetti, S Pilotti, et al.
Breast Cancer Research and Treatment|July 1, 1997
Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patientsM Zambetti, R Demicheli, D De Candis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
Multimodal treatment with primary single-agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo Cooperative GroupG Bonadonna, M Zambetti, C Bumma, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 17, 2011
Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) studyV Semiglazov, W Eiermann, M Zambetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year resultsA M Gianni, S Siena, M Bregni, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
American Journal of Clinical Oncology|June 1, 1990
Cisplatin and cyclophosphamide in advanced ovarian carcinoma: activity and toxicity of an ambulatory regimenM Zambetti, L Gianni, F Di Re, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1986
Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancerG Bonadonna, P Valagussa, G Tancini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2005
Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic processR Demicheli, R Miceli, A Moliterni, et al.
The International Journal of Biological Markers|October 1, 1989
Detection of Lewis(a) antigen in sera of ovarian carcinoma patients by MOv2-MOv8 double-determinant radioimmunoassayL Mantovani, V Azzini, S Canevari, et al.
Gynecologic Oncology|November 1, 1992
Nondysgerminomatous tumors of the ovary treated with cisplatin, vinblastine, and bleomycin: long-term resultsG De Palo, M Zambetti, S Pilotti, et al.
Breast Cancer Research and Treatment|July 1, 1997
Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patientsM Zambetti, R Demicheli, D De Candis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
Multimodal treatment with primary single-agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo Cooperative GroupG Bonadonna, M Zambetti, C Bumma, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 17, 2011
Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) studyV Semiglazov, W Eiermann, M Zambetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year resultsA M Gianni, S Siena, M Bregni, et al.
Pageof 5